Posts by

Brad Webb

Assurex Health Launches Collaboration with Canadian Mental Health Center

By Brad Webb / November 29, 2013 / 0 Comments

Our portfolio company Assurex Health just announced the creation of a partnership with Canada’s Center for Addiction and Mental Health (CAMH), one of the world’s leading research centers in the area of addiction and mental health and Canada’s largest mental health teaching hospital. CAMH will offer to Canadian citizens the firm’s pharmacogenomic test, GeneSight, which […]

Read More

Thomson Reuters and NuMedii Launch Initiative for Drug Discovery

By Brad Webb / November 6, 2013 / 0 Comments

Our portfolio company NuMedii just announced a groundbreaking collaboration with Thomson Reuters, the world’s leading information provider for businesses. The Thomson Reuters Science division has quietly been aggregating an enormous database of biological, clinical, and pharmacological information over the past few years. As a biotech startup, NuMedii is focused on revolutionizing drug discovery by reducing […]

Read More

Assurex Health Publishes Seminal Paper on Pharmacogenomics

By Brad Webb / November 2, 2013 / 0 Comments

Our portfolio company Assurex Health, announced recently the publication of a groundbreaking analysis of pharmacogenomic data in the International Review of Psychiatry. The publication strongly validates the premise that the clinical use of genomic testing to help predict patient response to psychiatric medications significantly improves treatment outcomes. This is a key milestone in the continuing […]

Read More

Genalyte Receives National Cancer Institute Grant

By Brad Webb / October 21, 2013 / 0 Comments

Our portfolio company Genalyte just announced the award of a government grant from the National Cancer Institute for the development of a  diagnostic system using Genalyte’s proprietary biomarker technology (see Genalyte Expands into Cancer Profiling with $1 Million NCI Grant to Develop Cancer Biomarker Panel). This project is a significant validation of the company’s capability […]

Read More

Genalyte and Colorado Diabetes Center Collaborate on Type 1 Diabetes

By Brad Webb / August 18, 2013 / 0 Comments

Earlier this week one of our portfolio companies, Genalyte, Inc., announced the release of a groundbreaking diagnostic system for early detection of Type 1 diabetes. This is of special significance to me as the young daughter of a good friend almost died due to undiagnosed Type 1 Diabetes – she was discovered by her parents […]

Read More

NuMedii Founder Atul Butte, MD, PhD honored at White House; Claremont Creek Ventures continues investment in health care Big Data.

By Brad Webb / June 20, 2013 / 0 Comments

Thursday June 20, 2013, Atul Butte, MD, PhD, a Stanford University Professor and entrepreneur is being honored at a formal ceremony in the White House Rose Garden in Washington DC.  The Obama Administration is honoring Dr. Butte and several other genomics and molecular biology researchers who have focused on making large and complex sets of […]

Read More

Meet our team

Claremont Creek Ventures was founded in 2005 by Nat Goldhaber, John Steuart and Randy Hawks to pursue early stage investing in exceptional technology startups.

Nat_Boldhaber7718 -1200px

NAT GOLDHABER

Nat Goldhaber is a co-founder of Claremont Creek Ventures. 

TED DRISCOLL

Ted is an expert on digital health and diagnostics, from big data and health technology to genomics and personalized medicine.

Paul_Straub7765 -1200px

PAUL STRAUB

Paul is particularly focused on the potential of digital and business innovation to impact and advance broad-impact industries.

Brad_Webb8124 1200px crop

BRAD WEBB

Brad is focused on the role of genomics and biomarker data analytics in driving the next generation of diagnostics and drug development.

Randy_Hawks7690 -1200px

RANDY HAWKS

Randy Hawks is a co-founder of Claremont Creek Ventures.

Post Categories

Archives